Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05382572 · ClinicalTrials.gov registry record
Pulmonary Fibrosis Foundation Community Registry
A clinical trial of Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease, sponsored by Pulmonary Fibrosis Foundation.
- Recruiting
- Registry status
- 10,000
- Enrollment target
- 1
- Study location
NCT05382572: Recruiting study of Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease, sponsored by Pulmonary Fibrosis Foundation.
NCT05382572 is a study of Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease that is actively recruiting participants, run by Pulmonary Fibrosis Foundation. The registered enrollment target is 10,000 participants, above the 555-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (1702% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05382572, a study of Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease, is actively recruiting participants, sponsored by Pulmonary Fibrosis Foundation.
- RECRUITING
- Registry status
- 10,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Pulmonary fibrosis (PF) results from a diverse group of health conditions and affects the lives of patients (including those who are post lung transplant), caregivers and family members. The Pulmonary Fibrosis Foundation Community Registry will offer an online portal where participants can self-enroll and directly contribute information about their experience with PF to be compiled into a longitudinal data set for use by researchers.
Conditions Studied
Study Locations (1)
Illinois
- Pulmonary Fibrosis Foundation - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,000 participants |
| Start Date | 2022-07-11 |
| Est. Completion | 2027-07-01 |
What NCT05382572 shows while recruiting
NCT05382572 is an observational study that tracks outcomes without assigning an intervention. Its 10,000 participants enrollment target places it among the larger protocols in the corpus, above the 555-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (1702% higher).
The record links to 4 conditions, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 0 interventions.
NCT05382572 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT05382572 about?
NCT05382572 is a clinical study titled "Pulmonary Fibrosis Foundation Community Registry". Pulmonary fibrosis (PF) results from a diverse group of health conditions and affects the lives of patients (including those who are post lung transplant), caregivers and family members. The Pulmonary Fibrosis Foundation Community Registry will offer an online portal where participants can self-enro...
What is the current status of trial NCT05382572?
This trial is currently recruiting. The enrollment target is 10,000 participants. The study started on 2022-07-11. Estimated completion is 2027-07-01.
What conditions does trial NCT05382572 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Pulmonary Fibrosis, Lung Fibrosis.
Who is sponsoring clinical trial NCT05382572?
This trial is sponsored by Pulmonary Fibrosis Foundation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05382572 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05382572's enrollment target sits among peer trials
10,000 2nd of 51 the highest of 51 other Idiopathic Pulmonary Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Idiopathic Pulmonary Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis
RECRUITING · Early Phase 1
-
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
RECRUITING · Phase 2
-
Interstitial Lung Disease Research Unit Biobank
RECRUITING
-
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00160771 · 10,000 participants
Biomechanics/Motion Analysis Laboratory Data Bank
- NCT00896935 · 10,000 participants
Arizona Cancer Center Biospecimen Repository
- NCT00898235 · 10,000 participants
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
- NCT00992303 · 10,000 participants
Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI